Holen Sie sich die Stockscreener-App
6.50
1.40%
0.09
Schlusskurs vom Vortag:
$6.41
Offen:
$6.36
24-Stunden-Volumen:
253.23K
Relative Volume:
0.84
Marktkapitalisierung:
$167.71M
Einnahmen:
$34.26M
Nettoeinkommen (Verlust:
$-46.61M
KGV:
-1.2547
EPS:
-5.1806
Netto-Cashflow:
$-62.01M
1W Leistung:
-6.74%
1M Leistung:
-12.75%
6M Leistung:
+29.48%
1J Leistung:
+26.71%
1-Tages-Spanne:
$6.105
$6.50
1-Wochen-Bereich:
$6.00
$7.38
52-Wochen-Spanne:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.50 | 165.39M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlitetm in Landmark CREDENCE Trial - Lelezard
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
Director at Precision Bio (NASDAQ: DTIL) receives 20,979 restricted stock units - Stock Titan
Precision Biosciences (DTIL) director receives grant of 20,979 restricted stock units - Stock Titan
Precision BioSciences (DTIL) director receives grant of 20,979 RSUs - Stock Titan
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility - AD HOC NEWS
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award - Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel - Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Guggenheim Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $19 - Moomoo
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Shareholders Approve Incentive Plan and Directors - The Globe and Mail
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Precision BioSciences (DTIL) Unveils Groundbreaking Data on PBGE - GuruFocus
Precision BioSciences Put Its ARCUS Gene Editing Data Front And Center - Finimize
Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial ResultsSlideshow (NASDAQ:DTIL) 2026-05-27 - Seeking Alpha
Precision BioSciences stock jumps on hepatitis B trial data By Investing.com - Investing.com South Africa
Precision BioSciences stock jumps on hepatitis B trial data - Investing.com
Precision BioSciences Reports Promising New Hepatitis B Trial Data - TipRanks
Why Is Precision BioSciences Stock Gaining Wednesday?Precision BioSciences (NASDAQ:DTIL) - Benzinga
Precision BioSciences Approves Amendments to 2019 Incentive Award Plan and Certificate of Incorporation - Minichart
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - BioSpace
New PBGENE-HBV hepatitis B data from Precision BioSciences (Nasdaq: DTIL) - Stock Titan
Experimental gene edit targets hepatitis B DNA in early patient biopsies - Stock Titan
Precision BioSciences (DTIL) shareholders approve 3.8M-share incentive plan increase and officer exculpation - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Precision Biosciences (DTIL) director gains 21,000 shares as RSUs vest into common stock - Stock Titan
Director at Precision BioSciences (DTIL) sees 21,000 RSUs vest into common stock - Stock Titan
Director Melinda Brown receives 21,000 DTIL shares as RSUs vest (DTIL) - Stock Titan
Precision BioSciences (DTIL) director gains 21,000 shares from RSU vesting - Stock Titan
Precision Biosciences (NASDAQ: DTIL) director’s 21,000 RSUs vest into shares - Stock Titan
DTIL: Shareholders approved all proposals as the company advanced key clinical programs and strengthened its finances - TradingView
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINA - pharmiweb.com
Precision BioSciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 - marketscreener.com
Precision BioSciences stock (US74019P1084): earnings miss and volatile recovery in gene editing play - AD HOC NEWS
Precision BioSciences stock (US74019P1084): gene-editing player in focus after fresh ECUR?506 trial - AD HOC NEWS
Newborn gene trial cuts life-threatening ammonia crises by up to 65% - Stock Titan
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Australia
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):